Back to Sectors

ORMP

ORAMED PHARMACEUTICALS INC.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 3/26/2026 | margin expansionBULLISH | 80% | 3/26/2026 | divestitureBULLISH | 50% | 3/26/2026 | dividend changeBEARISH | 60% | 3/26/2026 | dilution riskBULLISH | 90% | 5/19/2026 | earnings beatBULLISH | 70% | 5/19/2026 | margin expansionBULLISH | 60% | 5/19/2026 | dividend changeBULLISH | 80% | 5/19/2026 | acquisitionMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 19

Net income swung from a loss to $38.3 million due to fair-value revaluations.

earnings beat
90%
bullishMay 19

Operating loss decreased by 30% through aggressive R&D and G&A cost cutting.

margin expansion
70%
bullishMay 19

Paid $10.36 million in special dividends to shareholders.

dividend change
60%
bullishMay 19

Executed strategic transaction with Lifeward, securing equity and revenue share.

acquisition
80%
bullishMar 26

Significant net income growth driven by fair-value revaluation of strategic assets.

margin expansion
70%
bullishMar 26

Transferred POD technology to Lifeward to eliminate standalone R&D burn.

divestiture
80%
bullishMar 26

Declared a $0.25 per share special dividend to return capital to shareholders.

dividend change
50%
bearishMar 26

Potential for significant dilution from convertible notes and unfunded dividend obligations.

dilution risk
60%

Filing History

10-QMay 19, 2026

The Q1 2026 filing presents a stark contrast between a sophisticated investment vehicle and a struggling biotech firm. Oramed has successfully offloaded the direct costs of R&D by transferring its POD™ technology to Lifeward, effectively transforming its business model into a holding company for medical technology. The resulting surge in net income is a signal of the potential value within its portfolio, particularly Alpha Tau and Lifeward, but it also highlights the company's total dependence on the performance of third-party entities for its financial viability. Investors are now faced with a trade-off between the company's newfound agility as a strategic operator and the inherent risks of its dwindling cash runway. While the reduction in operating losses is a positive trend, the reliance on fair-value marks creates a high-beta profile where the stock's value is tied to clinical readouts and regulatory approvals of its investees. The ultimate success of this pivot depends on whether Oramed can convert these paper gains into sustainable cash flows before its current liquidity is exhausted.

10-KMar 26, 2026

The 10-K filing marks a definitive shift in Oramed's identity, moving away from the traditional biotech model toward a hybrid of an investment fund and a royalty holding company. The successful transfer of the POD platform to Lifeward removes the immediate burden of R&D funding, but it also ties Oramed's future success to the operational performance of third-party entities. The tension for investors lies between the immediate appeal of a cash-rich balance sheet and the long-term uncertainty of its non-operating income streams. Ultimately, the filing highlights a high-stakes trade-off: Oramed has successfully de-risked its clinical failure profile but has increased its exposure to market volatility and credit risk from its partners. The upcoming H2 2026 clinical trial and the performance of its Alpha Tau and Lifeward stakes will be the primary determinants of whether this pivot creates sustainable value or merely delays an inevitable capital shortfall.